Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator

New England Journal of Medicine

Volumn 364, Issue 4, 2011, Pages 303-312

  Hemmelgarn, Brenda R ^a,b,c   Moist, Louise M ^e   Lok, Charmaine E ^f   Tonelli, Marcello ^c   Manns, Braden J ^a,b,c   Holden, Rachel M ^g   LeBlanc, Martine ^h   Faris, Peter ^b,d   Barre, Paul ⁱ   Zhang, Jianguo ^a   Scott Douglas, Nairne ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ALBERTA HEALTH SERVICES   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HEPARIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CATHETER COMPLICATION; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COST EFFECTIVENESS ANALYSIS; DIALYSIS CATHETER; FEMALE; HAZARD RATIO; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 79251474918     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1011376     Document Type: Article

References (38)

1. Mendelssohn DC, Ethier J, Elder SJ, Saran R, Port FK, Pisoni RL. Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). Nephrol Dial Transplant 2006;21:721-8.
2. Moist LM, Trpeski L, Na Y, Lok CE. Increased hemodialysis catheter use in Canada and associated mortality risk: data from the Canadian Organ Replacement Registry 2001-2004. Clin J Am Soc Nephrol 2008;3:1726-32.
3. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 2009;4:Suppl 1:S5-S11.
4. Develter W, De Cubber A, Van Biesen W, Vanholder R, Lameire N. Survival and complications of indwelling venous catheters for permanent use in hemodialysis patients. Artif Organs 2005;29:399-405. (Pubitemid 41632982)
5. Little MA, O'Riordan A, Lucey B, et al. A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. Nephrol Dial Transplant 2001;16:2194-200. (Pubitemid 33062143)
6. Ponikvar R, Buturović-Ponikvar J. Temporary hemodialysis catheters as a long-term vascular access in chronic hemodialysis patients. Ther Apher Dial 2005; 9:250-3. (Pubitemid 41099510)
7. Swartz RD, Messana JM, Boyer CJ, Lunde NM, Weitzel WF, Hartman TL. Successful use of cuffed central venous hemodialysis catheters inserted percutaneously. J Am Soc Nephrol 1994;4:1719-25.
8. Trerotola SO, Johnson MS, Harris VJ, et al. Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology 1997;203:489-95.
9. Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
10. Stas KJ, Vanwalleghem J, De Moor B, Keuleers H. Trisodium citrate 30% vs. heparin 5% as catheter lock in the interdialytic period in twin- or double-lumen dialysis catheters for intermittent haemodialysis. Nephrol Dial Transplant 2001;16: 1521-2. (Pubitemid 32640629)
11. Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005;16:2769-77.
12. Clase CM, Crowther MA, Ingram AJ, Cinà CS. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. J Thromb Thrombolysis 2001;11:127-36.
13. Macrae JM, Loh G, Djurdjev O, et al. Short and long alteplase dwells in dysfunctional hemodialysis catheters. Hemodial Int 2005;9:189-95.
14. Tumlin J, Goldman J, Spiegel DM, et al. A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3. Clin J Am Soc Nephrol 2010;5:631-6.
15. Schenk P, Rosenkranz AR, Wölfl G, Hörl WH, Traindl O. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. Am J Kidney Dis 2000;35:130-6.
16. Hemmelgarn BR, Moist L, Pilkey RM, et al. Prevention of catheter lumen occlusion with rT-PA versus heparin (PreCLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrol 2006;7: 8.
17. Little MA, Walshe JJ. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 2002;39: 86-91.
18. Vascular Access Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006;48:Suppl 1:S248-S273.
19. Saran R, Bragg-Gresham JL, Rayner HC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003;64:254-62.
20. Preventing infections associated with indwelling intravascular access devices. Can Commun Dis Rep 1997;23:Suppl 8:1-32.
21. Manns B, Tonelli M, Yilmaz S, et al. Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. J Am Soc Nephrol 2005;16:201-9. (Pubitemid 43073174)
22. Lee T, Barker J, Allon M. Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis 2005;46:501-8. (Pubitemid 41208186)
23. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001;12:951-5. (Pubitemid 32756865)
24. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular Thrombolytic to Open Occluded Lines trial. J Clin Oncol 2002;20:317-24.
25. Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009;374:159-69.
26. Kalmanti M, Germanakis J, Stiakaki E, et al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatr Hematol Oncol 2002;19:173-9. (Pubitemid 34492214)
27. Kethireddy S, Safdar N. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials. J Vasc Access 2008;9:51-7. (Pubitemid 351618716)
28. Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 2001;59:1935-42.
29. Saad TF. Central venous dialysis catheters: catheter-associated infection. Semin Dial 2001;14:446-51.
30. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003;348:1123-33.
31. Jain G, Allon M, Saddekni S, Barker JF, Maya ID. Does heparin coating improve patency or reduce infection of tunneled dialysis catheters? Clin J Am Soc Nephrol 2009;4:1787-90.
32. Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136-42.
33. James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hemmelgarn BR. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008;148:596-605.
34. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004;66:801-5.
35. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 2004;44:779-91.
36. Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis 2009;53:1034-41.
37. Solomon LR, Cheesbrough JS, Ebah L, et al. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis 2010;55:1060-8.
38. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407. [Erratum, N Engl J Med 2010;362:1450.]